Veloxis appoints Alastair McEwan as new Chief Operating Officer
Alastair McEwan has been involved in pharmaceutical development and commercialization for over twenty years. He has broad general management, financial and M & A expertise derived from his past roles including President, Global Clinical at Inveresk Research and CFO of Cornerstone Therapeutics during its expansion and integration of EKR and its subsequent sale to Chiesi Farmaceutici.
At the same time John Weinberg steps down as Chief Operating Officer.
“We are very pleased that Alastair McEwan has accepted our invitation to join Veloxis as its Chief Operating Officer. “Alastair brings substantial operational and financial experience to the Company. We believe that, with the addition of Alastair to the executive management team, the Company is well positioned for future growth”, said Craig Collard, CEO. “At the same time, we would like to thank John Weinberg for his instrumental role in building the commercial infrastructure”.
For more information, please contact:
Veloxis Pharmaceuticals A/S
Craig A. Collard
President & CEO
Phone: +1 919 524 4317
Email: cac@veloxis.com